›› 2002, Vol. 1 ›› Issue (10): 18-21.

• 论著 • 上一篇    下一篇

左旋肉毒碱(可益能)在血液透析患者中的临床应用研究

张晓洁 刘惠兰   

  1. 100038 北京,首都医科大学附属复兴医院肾内科
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2002-10-19 发布日期:2002-10-19

  • Received:1900-01-01 Revised:1900-01-01 Online:2002-10-19 Published:2002-10-19

摘要: 【摘要】目的 研究尿毒症维持性血液透析患者血浆肉毒碱水平及静脉补充左旋肉毒碱(可益能)后的临床疗效。方法 选择本透析中心50例病情稳定、透析2年以上的维持性血液透析患者,应用酶法检测其透析前后的血浆肉毒碱水平后,将其随机分为两组,治疗组于每次透析结束时静脉注射左旋肉毒碱5ml(1克),对照组静脉注射等量的生理盐水,共应用2个月(26次透析)。复查两组患者血浆左旋肉毒碱水平及前白蛋白、转铁蛋白、白蛋白、血脂、血红蛋白浓度等,同时应用症状分级评分法观察两组用药前后体力、精神状态、食欲、恶心、呕吐、心功能、心悸、心律失常、肌肉疼痛、骨痛、透析低血压、肌肉痉挛、透析后虚弱无力持续时间等临床症状的变化情况和可能出现的不良反应。结果 ①两组患者存在明显的肉毒碱缺乏。②治疗组静脉补充可益能2月后,透析前后血浆肉毒碱水平均显著升高(P<0.01),透析后仍维持在正常值水平。对照组透析前后血浆肉毒碱水平无明显变化。③治疗组血浆前白蛋白、转铁蛋白、白蛋白较治疗前显著提高(P<0.05),干体重也显著增加(P<0.05)。对照组上述指标均无显著性变化。④治疗组血甘油三脂、总胆固醇、低密度脂蛋白与治疗前比较无显著性变化,但高密度脂蛋白较治疗前显著升高(P<0.05)。对照组血脂四项均无显著性变化。⑤治疗组体力、精神、食欲、心悸、心律失常、透析后虚弱无力持续时间等症状明显改善(P<0.01),对照组临床症状无明显变化。除1例出现一过性转氨酶升高外,应用可益能治疗组患者未出现不良反应。结论 维持性血液透析患者普遍存在肉毒碱缺乏,应用可益能治疗可安全、有效治疗肉毒碱缺乏症。

关键词: 左旋肉毒碱, 血液透析, 肉碱毒缺乏症

Abstract:

【Abstact】Objective To evaluate the plasma carnitine level and the effect of carnitine supplementation on hemodialysis patients. Methods 50 stable hemodialysis patients were selected and divided into two groups, 25 patients received intravenous L-carnitine after each dialysis session in a dosage of 1g for two months, the other 25 patients received placebo. Plasma carnitine level, pre-albumin, albumin, transferrin, blood lipid, hemoglobin and clinical symptoms were studied.Results The plasma carnitine level were lower than normal in hemodialysis patients. After L-carnitine supplementation, plasma carnitine, pre-albumin, albumin, transferrin, HDL were significantly elevated (P<0.05), Physical and mental status, appetite, arrhythmia,dialysis tolerance were improved in the treated groups. The parameters were not significantly changed in placebo groups. Conclusion L-carnitine supplementation can treat the carnitine deficiency in hemodialysis patients effectively.

Key words: Hemodialysis, Carnitine deficiency